Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of narcolepsy with or without cataplexy~* patients need to free of or discontinue psychostimulant medications for at least 14 days,~* patients with severe cataplexy are permitted to remain on their anticataplectic medications at stable doses~* patients must have adequate support to comply with the entire study requirements~Exclusion Criteria:~* Other conditions than Narcolepsy that can be considered as the primary causes of excessive daytime sleepiness~* Patients who are unable or unwilling to temporarily discontinue any no-authorized drugs or substances~* Psychiatric and neurological disorders such as psychosis or dementia, bipolar illness, severe anxiety, clinical depression, history of seizure disorder or other problem that in the investigator's opinion would preclude the patient's participation~* Current or recent history of a substance abuse or dependence disorder including alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BF2.649 (Type: EXPERIMENTAL): None
- Modafinil (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).